Sana Biotechnology (SANA) EBITDA (2020 - 2026)
Sana Biotechnology (SANA) posted EBITDA of -$48.6 million for Q1 2026, up 20.56% sequentially from -$61.2 million in Q4 2025, and up 3.98% YoY from -$46.8 million in Q1 2025.
Sana Biotechnology (SANA) EBITDA (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported EBITDA for 7 years, with the latest figure at -$48.6 million in Q1 2026.
- Quarterly EBITDA rose 3.98% year-over-year to -$48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.3 million (down 16.78% YoY) and the FY2025 annual result came in at -$250.3 million, up 8.21% from the prior year.
- EBITDA improved to -$48.6 million in Q1 2026 per SANA's latest filing, from -$61.2 million in the prior quarter.
- Over five years, EBITDA peaked at -$2.2 million in Q3 2023 and troughed at -$116.3 million in Q2 2023.
- A 5-year average of -$66.9 million and a median of -$61.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA surged 97.47% in 2023, then slumped 2731.77% in 2024.
- Over 5 years, EBITDA stood at -$81.8 million in 2022, then fell by 10.8% to -$90.6 million in 2023, then jumped by 43.87% to -$50.9 million in 2024, then dropped by 20.31% to -$61.2 million in 2025, then grew by 20.56% to -$48.6 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$48.6 million, -$61.2 million, and -$43.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | -65.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -65.42 Mn |
| Mar 31, 2026 | -48.61 Mn |
| Dec 31, 2025 | -61.20 Mn |
| Sep 30, 2025 | -43.52 Mn |
| Jun 30, 2025 | -94.98 Mn |
| Mar 31, 2025 | -50.63 Mn |
| Dec 31, 2024 | -50.87 Mn |
| Sep 30, 2024 | -61.76 Mn |
| Jun 30, 2024 | -49.37 Mn |
| Mar 31, 2024 | -110.72 Mn |
| Dec 31, 2023 | -90.62 Mn |
| Sep 30, 2023 | -2.18 Mn |
| Jun 30, 2023 | -116.29 Mn |
| Mar 31, 2023 | -84.05 Mn |
| Dec 31, 2022 | -81.79 Mn |
| Sep 30, 2022 | -86.19 Mn |
| Jun 30, 2022 | -72.90 Mn |
| Mar 31, 2022 | -31.69 Mn |
| Dec 31, 2021 | -111.28 Mn |
| Sep 30, 2021 | -83.43 Mn |